• Lilly Reports Second-Quarter Results

    INDIANAPOLIS, July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2017. $ in millions, except per share dat…

  • Lilly and Incyte Provide Update on Baricitinib

    INDIANAPOLIS, July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that a resubmission to the U.S. Food and Drug Administration (FDA) f…

  • Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy

    INDIANAPOLIS and SAN FRANCISCO, July 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Nektar Therapeutics (NASDAQ: NKTR) have announced a strategic collaboration to co-develop NKTR-358,…

  • 50 years uniting care with discovery

    Today’s guest blog comes from Mike Hutton, Chief Scientific Officer, Neurodegeneration, Eli Lilly and Company It’s often said that R&D in the pharmaceutical sector is a complex and long term under…

  • Working Together to Grow Canada’s Life Sciences Economy

    Today’s guest post comes from Lisa Matar, President and General Manager at Lilly Canada. As a child in Scarborough, Bill Blair’s parents would often drive him by the Lilly Canada office. At 5 years ol…